tissue -type plasminogen activator(t-PA )

Expression of human tissue-type plasminogen activator in cow mammary gland;

人组织型纤溶酶原激活剂牛乳腺生物反应器的研究

Studies on thrombolysis of recombinant human tissue-type plasminogen activator(rht-PA)and its mutants;

重组人组织型纤溶酶原激活剂及其突变体的溶血栓研究

Trichoderma reesei 306 was a recombinant strain that can produce tissue-type plasminogen activator(t-PA).

里氏木霉(Trichoderma reesei)306是能够生物合成组织型纤溶酶原激活剂(t-PA)的基因工程菌株。

Expression of tPAcDNA Gene in BHK 21 Cell;

组织型纤溶酶原激活剂cDNA在BHK21细胞中的表达

The Expression of tPA Directed by the Bovine BLG Regulatory Elements in the Mammary Gland of Transgenic Mice;

牛β-乳球蛋白基因调控序列指导组织型纤溶酶原激活剂在小鼠乳腺中的表达

From the point of view of large-scale and rapid purification of tPA, a variety of methods for the purification of tPA and the separation of single-chain and two-chain tPA were reviewed.

简述了用于大规模生产组织型纤溶酶原激活剂(tPA)的重组动物细胞及其培养工艺。

Construction of tissue plasminogen activator eukaryotic expression vector and its expression in MCF-7 cell line;

组织型纤溶酶原激活剂真核表达载体的构建及其在乳癌细胞系MCF-7中的瞬时表达

Construction of human tissue plasminogen activator minigene;

人组织型纤溶酶原激活剂突变体微小基因的构建

Changes and its clinical significance of serum brain-derived neurotrophic factor level and plasma tissue plasminogen activator level in patients with amnestic mild cognitive impairment;

遗忘型轻度认知功能损害患者血清脑源性神经营养因子及血浆组织型纤溶酶原激活剂水平变化及其临床意义

The therapeutic effect and changes of neurofunction deficit score, tissue type plasminogen activator (tPA), plasminogen activator inhibitor (PAI), antithrombin Ⅲ (AT Ⅲ), th.

观察两组患者治疗后有效率 ,治疗前后神经功能缺损评分、组织型纤溶酶原激活剂 (tPA)、纤溶酶原激活物抑制剂 (PAI)、抗凝血酶 Ⅲ (AT Ⅲ )、血栓素B2 (TXB2 )及 6 -酮 -前列腺素F1α(6 keto PGF1α)的变化。

The releases of tissue type plasminogen activator (t PA) and plasminogen activator inhibitor 1(PAI 1) were determined.

方法　培养的人脐静脉血管内皮细胞分别与剂量为 0 ,1,2 ,4 ,8mg/L的蝎毒素IV孵育后 ,测定蝎毒素IV对内皮细胞释放组织型纤溶酶原激活剂 (t PA)、组织型纤溶酶原激活剂抑制物(PAI 1)的影响。

The tissue type plasminogen activator (t-PA) is a primary factor in fibrinolysis system.

组织型纤溶酶原激活剂(tissue plasminogen activator, t-PA)是纤溶系统的重要因子,外源性t-PA作为溶栓药物的研制在国内外一直是抗血栓药物研发的热点。

Fibrin agarose plate assay(FAPA) is a kind of procedure detecting the in vitro fibrinolysis activity of plasminogen activators(PAs) such as urokinase(UK) and tissue-type plasminogen activator(t-PA).

在原有的纤维蛋白平板溶圈法 (fibrin agarose plate assay,FAPA)检测系统中引入纤溶酶原 (plasminogen) ,使该法检测组织型纤溶酶原激活剂 (tissue plasminogen activator,t- PA)的灵敏度提高 30倍以上 ,达到 0 。

The levels of tissue-plasminogen activator(t-PA) and plasminogen activator inhibitor-1(PAI-1) in blood plasma were detected by ELISA.

方法:随机选择72例心病血瘀证患者、20例心病非血瘀证患者与20例健康人,采用ELISA法检测血浆组织型纤溶酶原激活剂(t-PA)及抑制物(PAI-1)。

Comparison of Recombinant Tissue Plasminogen Activator, Urokinase and Defibrase in Vitro Simulation of Thrombolytic Test

重组织型纤溶酶原激活剂、尿激酶和降纤酶体外溶栓效果比较

Evaluation of the therapeutic effect of thrombolytic therapy with rt-PA and nursing intervention in patients with acute myocardial infarction

急性心肌梗死重组组织型纤溶酶原激活剂溶栓治疗的观察及护理

Therapeutic effect observation of thrombolysis with rt-PA intravenous in recurrent cerebral infarction

重组组织型纤溶酶原激活剂对再发性脑梗死静脉溶栓治疗评价

Therapeutic Effect of Ultra Earlier Thrombolysis of Recombinant Tissue Plasminogen Activator in Acute Cerebral Infarction

重组组织型纤溶酶原激活剂超早期溶栓治疗急性脑梗死的疗效

Thrombolytic therapy with intravenous recombinant tissue plasminogen activator for acute cerebral infarction

重组组织型纤溶酶原激活剂静脉溶栓治疗急性脑梗死19例

The Recombinant Human Tissue-type Plasminogen Activator in the Treatment of Deep Venous Thrombosis of the Lower Extremities

重组组织型纤溶酶原激活剂治疗下肢深静脉血栓形成的临床应用

Experimental study on prevention of the peritoneal adhesion by recombinant tissue-type plasminogen activator on rats

重组组织型纤溶酶原激活剂预防大鼠腹腔粘连的实验研究

Therapeutic effect evaluation of recombinant tissue plasminogen activator in hyper acute cerebral infarction

重组组织型纤溶酶原激活剂治疗急性脑梗死的疗效评价

Construction of Tissue-type Plasminogen Activator Variants and Their Expression in Prokaryotic and Eukaryotic Cells;

组织型纤溶酶原激活剂（t-PA）突变体的构建及其表达研究

Construction of Eukaryotic Expessing Vector of Tissue Plasminogen Activator (t-PA);

组织型纤溶酶原激活剂（t-PA）真核表达载体的构建

Advances in the Study of Tissue-type Plasminogen Activator and Its Toxicity in the Central Nervous System;

组织型纤溶酶原激活剂与中枢神经系统毒性的研究进展

Construction of Tissue Plasminogen Activator-annexin A5 Fusion Gene

组织型纤溶酶原激活剂—膜联蛋白A5融合基因的构建

Comparative study on intravenous rt-PA and uroninase thrombolytic strategy for acute myocardial infarction

重组组织型纤溶酶原激活剂与尿激酶静脉内溶栓治疗急性心肌梗死的比较研究

Therapeutic effects of thrombolysis with rt-PA intravenous in patients with ultra-acute vertebrobasilar artery infarction

重组组织型纤溶酶原激活剂超早期静脉溶栓治疗急性椎-基底动脉梗死的疗效观察

Intravenous thrombolysis with rt-PA on patients with acute cerebral infarction under the guide of multimodal magnetic resonance imaging

多模式磁共振指导下重组组织型纤溶酶原激活剂静脉溶栓治疗急性脑梗死

Therapeutic Efficacy of rt-PA Combined with Edaravone on Acute Cerebral Infarction

重组组织型纤溶酶原激活剂联合依达拉奉治疗急性脑梗死疗效观察

Studies of the Function and Mechanism of tPA on Sciatic Nerve Regeneration and Functional Recovery after Injury;

组织型纤溶酶原激活剂（tPA）在坐骨神经损伤与恢复过程中的作用研究

Clinical Study of the Expression of Tissue Factor and Urokinase Plasminogen Activator Receptor in Breast Cancer

组织因子、尿激酶型纤溶酶原激活剂受体在乳腺癌中的表达